Chimeric IL-12 Protein for Targeted NK Cell Stimulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using genetically modified NK cells face challenges in modulating cytotoxic activity due to the tumor microenvironment and systemic toxicity associated with IL-2 and IL-12 administration, with varying responses between primary and genetically modified NK cells.
Innovation Solution
Development of chimeric proteins comprising an IL-12 portion and a cancer cell targeting portion that induce targeted IFN-γ secretion in IL-2 sensitized or genetically modified NK cells, which constitutively express IL-2, to enhance cytotoxic activity while minimizing systemic toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If IL-2 and IL-12 are administered systemically to stimulate NK cells, then antitumor effects are enhanced, but systemic toxicity increases
Solution Approach 1:
The patent divides the treatment approach into two segments: (1) genetically modifying NK cells to constitutively express IL-2 internally, and (2) administering targeted IL-12 that binds specifically to tumor cells. This segmentation allows IL-12 to be delivered locally to the tumor site without systemic distribution, reducing toxicity while maintaining antitumor efficacy through the combined effect of IL-2-sensitized NK cells and localized IL-12 stimulation.
Solution Approach 2:
The patent uses tumor-targeting ligands (such as antibodies or peptides) as intermediaries to deliver IL-12 specifically to tumor cells. These targeting moieties act as mediators that guide the IL-12 to the intended destination, preventing systemic circulation and reducing off-target toxicity while ensuring concentrated IL-12 delivery at the tumor site where it can stimulate NK cells effectively.
2Productivity
If IL-12 concentration is increased to achieve therapeutic effect, then IFN-γ secretion is enhanced, but systemic toxicity increases
Solution Approach 1:
The patent applies local quality by concentrating IL-12 delivery specifically at the tumor site rather than distributing it systemically. The targeted IL-12 construct ensures high local concentration at the tumor where it can effectively stimulate NK cells to produce IFN-γ, while maintaining low or undetectable systemic levels, thereby achieving therapeutic effect without systemic toxicity.
Solution Approach 2:
Tumor-targeting ligands serve as intermediaries that carry IL-12 to the tumor site. These ligands bind to tumor-specific antigens or surface markers, delivering IL-12 directly to the tumor microenvironment where high concentrations are needed for IFN-γ induction, while preventing systemic circulation and associated toxicity.
3Reliability
If NK cells are genetically modified to enhance cytotoxic activity, then antitumor efficacy is improved, but response variability between primary and modified cells increases
Solution Approach 1:
The patent confers universality by making NK cells constitutively express IL-2 through genetic modification, giving them a universal baseline level of activation and sensitivity to IL-12 regardless of their original source (primary or cell line). This genetic endowment creates a standardized, predictable response profile across different NK cell preparations, enabling consistent therapeutic effects while retaining the ability to respond to targeted IL-12 stimulation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The chimeric proteins significantly enhance IFN-γ secretion in NK cells, promoting targeted cytotoxic activity and antigen presentation in tumors, reducing systemic toxicity and achieving therapeutically effective IL-12 concentrations at the tumor site.
Implementation Method 1
IL-2 and IL-12 cytokines elicit strong antitumor effects by stimulating unmodified immune cells, including T cells and natural killer (NK) cells. IL-12 is a stronger inducer of IFN-γ from unmodified NK cells and activated T cells.
Implementation Method 2
cell-based cancer treatments with genetically modified NK cells have gained attention due to positive treatment outcomes, particularly where NK92 derivatives such as activated NK cells (aNK cells), genetically modified NK cells with high affinity CD16 receptors (haNK cells), or chimeric antigen receptors (taNK cells) were used.
Implementation Method 3
chimeric proteins significantly enhance IFN-γ secretion in NK cells that express and intracellularly retain IL-2 as compared to native NK cells. such chimeric protein has substantially reduced systemic toxicity and moreover beneficially induces IFN-γ secretion in a targeted manner.
Data Source
AI summary
Compositions and methods for NK cell based treatments, and particularly NK cells that express and intracellularly retain IL-2, are presented in which the NK cells are stimulated with a chimeric protein that has a cancer cell targeting portion and an IL-12 portion. Beneficially, such chimeric protein has substantially reduced systemic toxicity and induces IFN-γ secretion in a targeted manner. Moreover, chimeric proteins contemplated herein also significantly enhanced IFN-γ secretion in NK cells that express and intracellularly retain IL-2 as compared to native NK cells. Preferred chimeric proteins comprise SEQ ID NO:1 or SEQ ID NO:2, and SEQ ID NO:3.